Abstract 2135P
Background
G8 and GA assessments to screen for frailty and facilitate appropriate interventions have been recommended by the International Society for Geriatric Oncology in older adults with cancer. The main objective of this study is to evaluate the impact of G8 and GA-based interventions on the QoL of older Asian adults with cancer.
Methods
This is a prospective study of cancer patients aged ≥70 treated at the National University Cancer Institute, Singapore. The G8, CGA, and EORTC QLQ 30 questionnaires were administered at study entry. Targeted interventions were offered by the multi-disciplinary geriatric oncology (GO) service. After three months, a follow-up EORTC QLQ 30 was repeated for those who required geriatric interventions. Primary outcome measure was comparison of pre/post- EORTC QLQ 30 scores.
Results
N=230 patients were accrued. Median age was 74 (range:70-90). Majority were male (56%), diagnosed with gastrointestinal cancers (35%) and receiving palliative intent treatment (60%). Based on GA, 11% were classified as frail, 58% as pre-frail and 31% as fit. 79% had G8 scores ≤14. Pre-frail, frail and those with G8 ≤14 had lower baseline EORTC QOL function scores and higher EORTC QOL symptom scores (p<0.05). They also had significantly shorter overall survival (OS) compared to fit or with patients G8>14. (HR=2.54 95% CI 1.46-4.43, p=0.001 for frail vs fit patients; HR=1.72 95% CI 1.18-2.53, p=0.005 for pre-frail vs fit patients; HR=1.51 95% CI 1.05-2.18, p=0.027 for G8 ≤14 vs >14). GO interventions were suggested for 144 patients with 104 patients completing a 2nd EORTC QOL questionnaire. These patients reported significant improvements in the EORTC emotional and social functioning domains (mean difference +4.6, p<0.001 and +12.3 p<0.001, respectively), a significant reduction in the EORTC symptom scale of pain, insomnia, constipation, and financial difficulties (mean difference -5.8 p=0.003, -8.3 p<0.001, -9.0 p<0.001, and -6 p=0.01), with no significant deterioration in other QOL domains.
Conclusions
Geriatric assessment-based targeted interventions delivered by a multidisciplinary GO service significantly improved multiple QOL domains in older Asian adults undergoing cancer treatment.
Clinical trial identification
DSRB Study Reference Number: 2017/00214.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
C.E. Chee: Financial Interests, Institutional, Advisory Board: Merck, AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07